Get quick access to your product right after purchase—no wait times.
Estimated to be delivered 0-24 H
Rest assured with our E-books digital products—delivered instantly via email! We stand by the quality of our digital offerings, but if you're not satisfied, we offer a hassle-free return policy.
You can request a refund for most digital purchases within 30 days of delivery. If you encounter any issues or if the product doesn't meet your expectations, simply contact our support team.
Although these digital products aren't physically returned, your satisfaction is our priority. Our team will work with you to ensure a smooth resolution or provide a refund promptly to your original payment method.
Shop with confidence! Enjoy the assurance of secure transactions with PayPal, a trusted and globally recognized payment gateway. Benefit from the safety and coverage of PayPal Buyer Protection, ensuring your purchase is secure and protected. Pay seamlessly with your credit or debit card through PayPal, providing you with an additional layer of security and convenience. Your peace of mind is our priority, and with PayPal, your transactions are backed by industry-leading safety measures and buyer guarantees.
Structure-Based Drug Design and Structural Biology Study of Novel Nonpeptide Inhibitors of Severe Acute Respiratory Syndrome Coronavirus Main Protease I-Lin Lu,†,‡ Neeraj Mahindroo,‡ Po-Huang Liang,§ Yi-Hui Peng,| Chih-Jung Kuo,§ Keng-Chang Tsai,‡ Hsing-Pang Hsieh,‡ Yu-Sheng Chao,‡ and Su-Ying Wu*,†,‡ Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan, Republic of China, DiVision of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, Taiwan, Republic of China, Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan, Republic of China, and Structural Biology Program, National Tsing Hua UniVersity, Hsinchu, Taiwan, Republic of China ReceiVed February 22, 2006 Severe acute respiratory syndrome coronavirus (SARS-CoV) main protease (Mpro), a protein required for the maturation of SARS-CoV, is vital for its life cycle, making it an attractive target for structure-based drug design of anti-SARS drugs. The structure-based virtual screening of a chemical database containing 58 855 compounds followed by the testing of potential compounds for SARS-CoV Mpro inhibition leads to two hit compounds. The core structures of these two hits, defined by the docking study, are used for further analogue search. Twenty-one analogues derived from these two hits exhibited IC50 values below 50 µM, with the most potent one showing 0.3 µM. Furthermore, the complex structures of two potent inhibitors with SARS-CoV Mpro were solved by X-ray crystallography. They bind to the protein in a distinct manner compared to all published SARS-CoV Mpro complex structures. They inhibit SARS-CoV Mpro activity via intensive H-bond network and hydrophobic interactions, without the formation of a covalent bond. Interestingly, the most potent inhibitor induces protein conformational changes, and the inhibition mechanisms, particularly the disruption of catalytic dyad (His41 and Cys145), are elaborated. Introduction Severe acute respiratory syndrome (SARS), a new respiratory disease caused by a novel coronavirus, SARS coronavirus (SARS-CoV),1,2 spread rapidly all over the world in 2003 and infected more than 8000 people, resulting in approximately 800 deaths worldwide with mortality rates reaching over 40% in certain populations.3,4 Developments of drugs and vaccines are vigorously being pursued, but these are still quite far from clinics. SARS-CoV, an enveloped positive-strand RNA virus from the Coronaviridae family,5 codes for two very large polyproteins, namely, pp1a (?450 kDa) and pp1b (?750 kDa), that mediate all the functions required for viral replication and transcription. To be functional, these polyproteins need to be processed by the 33.8 kDa main protease (Mpro), also called the 3C-like protease (3CLpro).6 For its important role in SARS-CoV matura- tion and infection, Mpro has been suggested as a promising target for anti-SARS agent design. The crystal structures of SARS-CoV Mpro have been solved recently,7-11 revealing that it forms a homodimer with three domains in each monomer. The antiparallel ?-barrel structure of domains I and II is similar to other coronavirus proteases and forms a chymotrypsin-like fold responsible for catalytic reactions. The catalytic dyad residues His41 and Cys145 are located at the cleft between domains I and II. The third domain, C-terminal R-helical domain, is very diverse among the picor- navirus and coronavirus Mpro. It has been reported that domain III existed as a stable dimer even at a very low concentration, indicating that this extra domain contributes to the dimerization of SARS-CoV Mpro and therefore switches the enzyme from the inactive form (monomer) to active form (dimer).12 Ad- ditionally, the N finger (residues N1?N7) located in the same area also contributes to the dimerization of the two monomers. Availability of protein structures and the biological character- istics of SARS-CoV Mpro provide insights on the substrate binding site, making it an attractive target for structure-based drug design in an effort to discover more potent and specific inhibitors against it. Inhibitors of SARS-CoV Mpro have been identified by various computational methods.13-19 For examples, Liu et al.14 and Dooley et al.15 identified the inhibitors using 3D structure derived from molecular dynamic simulation of SARS-CoV Mpro as a virtual screening target structure, while others used the pharmacophore model to predict potential inhibitors.20,21 The discovery efforts by computer-aided drug design showed only a few cases of SARS-CoV Mpro inhibition potency at micromolar range as confirmed by bioassay. These results indicate there is still a vacuum that needs to be filled to find more potent inhibitors against SARS-CoV Mpro. Moreover, although a number of nonpeptide inhibitors of SARS-CoV Mpro have been discovered, such as bifunctional arylboronic acids,22 isatin derivatives,23 polyphenols,24 etacrynic acid analogues,25 cinanserin,26 and other chemically diverse small molecules,15,27,28 the lack of structure biology information on these compounds and their interactions with SARS-CoV Mpro further makes the design more difficult. All the published structures up-to-date are complexed with peptidyl inhibitors through covalent bonding to SARS-CoV Mpro.7,8,10,11 Therefore, there is an urgent need to obtain the molecular insight of small molecule compounds to SARS-CoV Mpro to design more potent and specific drugs against it. In this study, we perform the structure-based virtual screening on a chemical database containing 58 855 compounds based on the 3D structure of SARS-CoV Mpro. Active compounds, selected from virtual screening approach and confirmed by the * To whom correspondence should be addressed. For H.-P.H.: phone, 886-37-246166, ext 35708; fax, 886-37-586456; e-mail,
Experience immediate satisfaction with our Ebooks digital products! Once your purchase is complete, your product is promptly delivered via email, ensuring zero wait times. Anticipate receiving your digital delivery within 0-24 hours, granting you rapid access to our premium digital offerings. Embrace efficiency with Ebooks—swiftly delivered straight to your inbox.
We are committed to your satisfaction with our Ebooks digital products. If, for any reason, you're unsatisfied, we offer a hassle-free return policy. You can request a refund for most digital purchases within 30 days of delivery. Contact our dedicated support team in case of any issues or if the product doesn't meet your expectations.
As these digital products aren't physically returned, your contentment remains our priority. Our team will diligently collaborate with you to ensure a smooth resolution or promptly process a refund to your original payment method. Your satisfaction is at the core of our commitment.
Thanks for subscribing!
This email has been registered!